Wayne Kuznar | Authors


Patients With Metastatic RCC Receive TKIs or mTOR Inhibitors After Immunotherapy

February 18, 2020

Most patients with metastatic renal cell carcinoma whose disease progresses after immunotherapy given either alone or in combination with other agents receive subsequent treatment with VEGF tyrosine kinase inhibitors or mTOR inhibitors. When administered post-immunotherapy, cabozantinib is associated with superior median progression free survival, according to retrospective data from a real-world study of patients treated at 16 Italian referral centers.

Effects of SBRT Plus Nivolumab Result in Responses for Certain RCC Subgroups

February 17, 2020

Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma, according to lead investigator Cristina Masini, MD, who presented the data at the 2020 Genitourinary Cancers Symposium.

Neoadjuvant Nivolumab Plus Chemotherapy Results in High Response Rates in Muscle-Invasive Bladder Cancer

February 15, 2020

Nivolumab plus gemcitabine and cisplatin administered in the neoadjuvant setting to patients with muscle-invasive bladder cancer resulted in a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49%.